1-(5-(but-1-yn-1-yl)-1H-indol-1-yl)ethanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-(5-(but-1-yn-1-yl)-1H-indol-1-yl)ethanone
• 英文别名: 1-(5-but-1-ynylindol-1-yl)ethanone
• 化学式: C₁₄H₁₃NO
• 分子量: 211.263
• InChiKey: QCBVSXKPBVXLDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  22
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(5-(but-1-yn-1-yl)-1H-indol-1-yl)ethanone 在 盐酸 、 二(氰基苯)二氯化钯 、 potassium carbonate 作用下， 以 四氢呋喃 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts

  摘要：

  Approximately 80% of breast cancers are estrogen receptor alpha, (ER-a) positive, and although women typically initially respond, well to antihormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges. Although a variety of resistance mechanism may be at play in this state, there is evidence that in many cases the ER still plays a central role, including mutations in the ER leading to constitutively active receptor. Fulvestrant is a steroid-based, selective estrogen receptor degrader., (SEED) That both antagonizes and degrades ER-alpha and is active in patients who have progressed on antihormonal agents. However, fulvestrant suffers from poor pharmaceutical properties and must be administered by intramuscular injections that limit the total amount of drug that can be administered and hence lead to the potential for incomplete receptor blockade. We describe the identification and characterization of a series of small-molecule, orally bioavailable SERDs, which are potent antagonists and degraders of ER-alpha and in which the ER-alpha degrading properties were prospectively optimized. The lead compound 111 (GDC-0810 or ARN-810) demonstrates robust activity in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer, and is currently in clinical trials in women with locally advanced or metastatic estrogen receptor-positive breast cancer.

  DOI：

  10.1021/acs.jmedchem.5b00054
• 作为产物：
  描述：

  5-碘吲哚 在 4-二甲氨基吡啶 、 copper(l) iodide 、 四(三苯基膦)钯 、 四丁基氟化铵 、 三苯基氯甲烷 作用下， 以 四氢呋喃 、 1,2-二氯乙烷 为溶剂， 生成 1-(5-(but-1-yn-1-yl)-1H-indol-1-yl)ethanone
  参考文献：
  名称：

  Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts

  摘要：

  Approximately 80% of breast cancers are estrogen receptor alpha, (ER-a) positive, and although women typically initially respond, well to antihormonal therapies such as tamoxifen and aromatase inhibitors, resistance often emerges. Although a variety of resistance mechanism may be at play in this state, there is evidence that in many cases the ER still plays a central role, including mutations in the ER leading to constitutively active receptor. Fulvestrant is a steroid-based, selective estrogen receptor degrader., (SEED) That both antagonizes and degrades ER-alpha and is active in patients who have progressed on antihormonal agents. However, fulvestrant suffers from poor pharmaceutical properties and must be administered by intramuscular injections that limit the total amount of drug that can be administered and hence lead to the potential for incomplete receptor blockade. We describe the identification and characterization of a series of small-molecule, orally bioavailable SERDs, which are potent antagonists and degraders of ER-alpha and in which the ER-alpha degrading properties were prospectively optimized. The lead compound 111 (GDC-0810 or ARN-810) demonstrates robust activity in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer, and is currently in clinical trials in women with locally advanced or metastatic estrogen receptor-positive breast cancer.

  DOI：

  10.1021/acs.jmedchem.5b00054

文献信息

• ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
  申请人：Smith Nicholas D.

  公开号：US20130231333A1

  公开（公告）日：2013-09-05

  Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

  本文描述了一些雌激素受体调节剂化合物。还描述了包括所述化合物的制药组合物和药物，以及使用这些雌激素受体调节剂，单独或与其他化合物结合，治疗与雌激素受体介导或依赖的疾病或症状的方法。
• Estrogen receptor modulators and uses thereof
  申请人：Smith Nicholas D.

  公开号：US09399646B2

  公开（公告）日：2016-07-26

  Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

  本文描述了一些雌激素受体调节剂化合物。还描述了包括上述化合物的药物组成物和药物，以及使用这些雌激素受体调节剂，单独或与其他化合物联合治疗介导或依赖于雌激素受体的疾病或状况的方法。
• [EN] ESTROGEN RECEPTOR MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DES RÉCEPTEURS DES OESTROGÈNES ET LEURS UTILISATIONS
  申请人：ARAGON PHARMACEUTICALS INC

  公开号：WO2012037411A9

  公开（公告）日：2012-05-18
• US9399646B2
  申请人：——

  公开号：US9399646B2

  公开（公告）日：2016-07-26
• US9868704B2
  申请人：——

  公开号：US9868704B2

  公开（公告）日：2018-01-16